Lyon: Research data on Sihuan Pharmaceutical's (00013.HK) savolitinib is improving, maintaining the "outperform market" rating.

Zhitong Financial APP learned that, Lyon released a research report stating that at the recent American Society of Clinical Oncology (ASCO) annual meeting, Hutchison Whampoa Medicine (00013.HK) announced the latest research results of the phase III clinical trial of savolitinib and osimertinib combination therapy for the treatment of non-small cell lung cancer in China. Lyon pointed out that the mid-term analysis results showed that compared to the control group, the treatment with savolitinib combined with osimertinib showed outstanding efficacy and good safety. The management mentioned that the overall survival trend is positive but not yet mature. Lyon expects that the new research data will benefit the expansion of indications for savolitinib in China and maintain the "outperform the market" rating for Hutchison Whampoa Medicine, with a target price of 30.7 Hong Kong dollars.